Pscilly

Psilocybin and Anhedonia: CU Anschutz Trial Reports Early Signal

By · Published

Researchers at the University of Colorado Anschutz in Aurora have published what they describe as the first randomized, placebo-controlled trial built specifically to test psilocybin against anhedonia in people with treatment-resistant depression. The results, published in the Journal of Affective Disorders and announced by the university on Nov. 17, are mixed but intriguing, and the team says they are preliminary.

Anhedonia is the reduced ability to feel interest, motivation or pleasure. It can drain the enjoyment out of hobbies, relationships and daily routines, and it is known for hanging on even when other parts of depression ease. That stubbornness is why the Colorado group chose to study it on its own rather than folding it into a single overall depression score.

How the trial worked

The double-blind study enrolled 20 adults with major depressive disorder that had not responded well to earlier treatment. Participants were randomly assigned to one of two groups: a 25-milligram dose of psilocybin or a 1-milligram comparison dose, which researchers use as an active placebo. Both groups received psychological support. The team measured anhedonia and overall depression severity one week and eight weeks after the session.

The trial was led by Andrew Novick, MD, PhD, an associate professor of psychiatry at CU Anschutz, whose lab has been studying psilocybin's effects on specific depression symptoms using brain imaging and other measures.

What the researchers found

The study's main test did not succeed. On its primary anhedonia measure at one week, the university said there was no statistically significant difference between the two groups.

The more encouraging result came later. At eight weeks, participants in the 25-milligram group showed significantly greater improvement in anhedonia than those in the comparison group. Because that was a secondary measure, the university framed it as a finding that warrants further investigation rather than proof of benefit. The higher-dose group also showed greater improvement in overall depression severity at both the one-week and eight-week check-ins.

Novick said anhedonia can be one of the most debilitating parts of depression because it affects whether people can find enjoyment, connection and meaning in everyday life. He added that depression is not a single experience, and that looking at individual symptoms may show which parts of the illness respond to psychedelic-assisted treatment and how those effects change over time.

Why the small study matters

The researchers were clear about the limits. With only 20 participants, the trial cannot settle whether psilocybin helps anhedonia, whether any effect lasts, or how it would work. The team said larger trials will be needed to confirm the results and to judge safety and effectiveness for this symptom.

Still, the study adds to a shift in psychedelic research away from broad depression scores and toward the symptoms that most shape people's lives. Late-stage drug programs have mostly been judged on overall depression scales, so trials focused on single symptoms could help explain why some patients respond and others do not.

The Colorado backdrop

The research lands in a state that has already gone further than most on psilocybin policy. Colorado voters approved Proposition 122 in 2022, creating a regulated natural medicine program for adults that operates separately from clinical research like the CU Anschutz trial. Colorado healing businesses listed on Pscilly, including Neuroalchemy Healing Center in Littleton, Reflective Healing in Fort Collins and Happy Rebel Healing in Boulder, operate under that state framework.

The CU Anschutz results are research findings, not a treatment recommendation. Psilocybin is not approved by the FDA for any condition and remains a Schedule I controlled substance under federal law. Anyone living with depression should talk with a qualified health professional about care options.

On Pscilly

Published
November 17, 2026
Place
Aurora, CO

Nearby